Jinling Pharmaceutical 過去の業績
過去 基準チェック /16
Jinling Pharmaceutical has been growing earnings at an average annual rate of 0.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 2.9% per year. Jinling Pharmaceutical's return on equity is 1.6%, and it has net margins of 2.5%.
主要情報
0.5%
収益成長率
-0.02%
EPS成長率
Pharmaceuticals 業界の成長 | 10.9% |
収益成長率 | 2.9% |
株主資本利益率 | 1.6% |
ネット・マージン | 2.5% |
前回の決算情報 | 30 Sep 2024 |
収支内訳
Jinling Pharmaceutical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Sep 24 | 2,902 | 73 | 425 | 101 |
30 Jun 24 | 2,855 | 74 | 424 | 89 |
31 Mar 24 | 2,824 | 100 | 429 | 86 |
31 Dec 23 | 2,786 | 100 | 424 | 79 |
30 Sep 23 | 2,721 | 110 | 412 | 71 |
30 Jun 23 | 2,760 | 124 | 401 | 82 |
31 Mar 23 | 2,686 | 110 | 386 | 79 |
01 Jan 23 | 2,671 | 105 | 385 | 74 |
30 Sep 22 | 2,752 | 116 | 379 | 63 |
30 Jun 22 | 2,739 | 104 | 383 | 54 |
31 Mar 22 | 2,800 | 125 | 385 | 60 |
01 Jan 22 | 2,809 | 121 | 383 | 57 |
30 Sep 21 | 2,796 | 85 | 393 | 54 |
30 Jun 21 | 2,783 | 117 | 380 | 47 |
31 Mar 21 | 2,692 | 128 | 351 | 41 |
31 Dec 20 | 2,504 | 65 | 328 | 44 |
30 Sep 20 | 2,413 | -13 | 306 | 45 |
30 Jun 20 | 2,389 | -58 | 303 | 47 |
31 Mar 20 | 2,435 | -93 | 324 | 45 |
31 Dec 19 | 2,535 | 145 | 349 | 44 |
30 Sep 19 | 2,532 | 359 | 343 | 34 |
30 Jun 19 | 2,623 | 380 | 375 | 30 |
31 Mar 19 | 2,721 | 405 | 392 | 29 |
01 Jan 19 | 2,899 | 242 | 427 | 34 |
30 Sep 18 | 3,032 | 113 | 521 | 49 |
30 Jun 18 | 3,046 | 126 | 489 | 60 |
31 Mar 18 | 3,152 | 141 | 496 | 53 |
31 Dec 17 | 3,192 | 137 | 479 | 39 |
30 Sep 17 | 3,391 | 170 | 410 | 18 |
30 Jun 17 | 3,481 | 171 | 431 | 0 |
31 Mar 17 | 3,540 | 175 | 439 | 0 |
31 Dec 16 | 3,579 | 180 | 444 | 0 |
30 Sep 16 | 3,526 | 200 | 459 | 0 |
30 Jun 16 | 3,462 | 202 | 443 | 0 |
31 Mar 16 | 3,379 | 199 | 459 | 0 |
31 Dec 15 | 3,221 | 208 | 446 | 0 |
30 Sep 15 | 3,061 | 197 | 430 | 0 |
30 Jun 15 | 2,958 | 204 | 437 | 0 |
31 Mar 15 | 2,849 | 214 | 426 | 0 |
31 Dec 14 | 2,772 | 197 | 407 | 0 |
30 Sep 14 | 2,781 | 196 | 429 | 0 |
30 Jun 14 | 2,708 | 183 | 410 | 0 |
31 Mar 14 | 2,639 | 166 | 382 | 0 |
31 Dec 13 | 2,606 | 156 | 378 | 0 |
質の高い収益: 000919 has a large one-off gain of CN¥31.5M impacting its last 12 months of financial results to 30th September, 2024.
利益率の向上: 000919's current net profit margins (2.5%) are lower than last year (4%).
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 000919's earnings have grown by 0.5% per year over the past 5 years.
成長の加速: 000919's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
収益対業界: 000919 had negative earnings growth (-33.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
株主資本利益率
高いROE: 000919's Return on Equity (1.6%) is considered low.